|8-K||current report||Apr 30, 2015||515.9 KB|
|8-K||current report||Apr 27, 2015||49.7 KB|
|DEF 14A||definitive proxy statement||Apr 16, 2015||635.0 KB|
|10-K||annual report||Mar 26, 2015||1.2 MB|
|8-K||current report||Mar 26, 2015||61.6 KB|
|PRE 14A||preliminary proxy statement||Mar 25, 2015||635.7 KB|
|SC 13G/A||amended statement of beneficial ownership||Feb 17, 2015||70.7 KB|
|8-K||current report||Feb 12, 2015||781.7 KB|
|4||cormack, scott daniel||Jan 30, 2015||26.0 KB|
|4||jacobs, cindy||Jan 30, 2015||25.9 KB|
|SC 13G/A||amended statement of beneficial ownership||Jan 27, 2015||51.2 KB|
|SC 13G/A||amended statement of beneficial ownership||Jan 26, 2015||26.3 KB|
|SC 13G/A||amended statement of beneficial ownership||Jan 16, 2015||38.6 KB|
|8-K||current report||Dec 30, 2014||53.1 KB|
|8-K||current report||Dec 19, 2014||53.0 KB|
|SC 13G||statement of beneficial ownership||Dec 12, 2014||80.9 KB|
|SC 13G||statement of beneficial ownership||Nov 7, 2014||38.6 KB|
|10-Q||quarterly report||Oct 30, 2014||462.8 KB|
|8-K||current report||Oct 30, 2014||56.1 KB|
|4||jacobs, cindy||Sep 19, 2014||25.9 KB|
- Corporate Governance
- Management & Board
- Stock Information
- SEC Filings
- Quarterly Results
- Analyst Coverage
- Webcasts & Presentations
- Scientific Publications & Presentations
- Frequently Asked Questions
© 2004-2017 OncoGenex Pharmaceuticals Inc. All rights reserved.
OncoGenex product candidates are investigational drugs for use only in approved clinical trials.
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
OncoGenex is uniquely focused on the challenge of cancer treatment resistance. We currently have several on-going clinical trials that may be of interest to you.
OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
OncoGenex develops novel compounds designed to meet the persistent challenge of treatment resistance across a variety of cancers.